Assessment Status | Awaiting full HTA submission from Applicant |
HTA ID | 23016 |
Drug | Ivosidenib |
Brand | Tibsovo® |
Indication | For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy |
Assessment Process | |
Rapid review commissioned | 08/03/2023 |
Rapid review completed | 17/04/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ivosidenib compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 28/06/2023 |
Pre-submission consultation with Applicant | 05/09/2023 |